News By Tag Industry News News By Place Country(s) Industry News
| ![]() New market study, "Abbott Laboratories: Company Analysis", has been publishedNew Pharmaceuticals market report from Datamonitor: "Abbott Laboratories: Company Analysis"
By: Fast Market Research, Inc. Scope * Gain insight into Abbott's strategic outlook across the next 6 years * Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source. Highlights Strategic insight into the prospects for Abbott over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales. Reasons to Get this Report * Benchmark Abbott's performance against key rivals in the prescription pharmaceutical sector * Examine how the spun out pharmaceuticals company Abbvie will fare as a standalone unit * Discover how Abbott has utilized M&A to become one of the world's largest multi-disciplinary healthcare companies ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Report Table of Contents: Abbott Laboratories: SCOPE OF ABBOTT ANALYSIS * PharmaVitae Explorer database * Analysis structure * Executive summary * Strategic insight * Company overview * Operating performance analysis * Data sourcing * Analyst consensus EXECUTIVE SUMMARY * Key findings * Abbott prescription pharmaceutical sales outlook * Abbott financial outlook * SWOT analysis * Strengths * Weaknesses * Opportunities * Threats STRATEGIC INSIGHT * Launch/core/ * M&A dictates Abbott's corporate strategy in run-up to AbbVie separation * Indian market expansion * Abbott has the leading share of the lucrative autoimmune disorder market * Abbott's heavy reliance on Humira continues * Weak pipeline undermines growth expectations * Innovative pharma split imminent COMPANY OVERVIEW * Key findings * Background * Corporate structure * Pharmaceuticals * Nutritionals * Diagnostics * Vascular * Other * M&A history * M&A strategy OPERATING PERFORMANCE ANALYSIS * Key findings * Reconciliation between PharmaVitae- * Operating costs and profit analysis * Operating costs and profit analysis, 2005-11 * Operating cost and profit analysis, 2011-17 APPENDIX * Exchange rates TABLES * Table: Datamonitor's established pharmaceutical company coverage, 2012 * Table: Abbott - key product overview ($m), 2011-17 * Table: Abbott's financial performance ($m), 2011-17 * Table: Abbott launch, core, and expiry portfolio overview ($m), 2011-17 * Table: AbbVie product portfolio sales ($m), 2011-17 * Table: AbbVie operating performance ($m), 2011-17 * Table: Abbott key merger and acquisition deals, 2001-11 * Table: Total Abbott sales by business unit ($m), 2005-11 * Table: Abbott operating revenue/cost analysis ($m), 2005-11 * Table: Abbott operating cost ratio analysis (percentage of total revenues), 2005-11 * Table: Abbott operating revenue/cost analysis ($m), 2011-17 * Table: Abbott operating cost ratio analysis (percentage of total revenues), 2011-17 * Table: Exchange rates, 2012 FIGURES * Figure: The PharmaVitae Explorer * Figure: Abbott's prescription pharmaceutical performance, sales ($m) and growth rate (%), 2005-17 * Figure: Abbott's financial performance ($m), 2005-17 * Figure: Abbott launch/core/ * Figure: Leading companies in the immunology and inflammation biologics space (%), 2005-17 * Figure: Abbott operating revenue/cost analysis ($m), 2005-17 About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. End
|
|